Macular Functional Changes in Patients With Neovascular Age-Related Macular Degeneration Receiving Ranibizumab Therapy (Lucentis)

BMC Geriatrics - United Kingdom
doi 10.1186/1471-2318-10-s1-a77
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine
Medicine
2006English

Ranibizumab Monotherapy in Neovascular Age-Related Macular Degeneration With Pigment Epithelial Detachment

Journal of Clinical & Experimental Ophthalmology
2012English

Macular Atrophy in Neovascular Age Related Macular Degeneration

Journal of Clinical Review & Case Reports
2019English

Ranibizumab in Neovascular Age-Related Macular Degeneration: A 5-Year Follow-Up

Clinical Ophthalmology
Ophthalmology
2016English

Visual Outcomes in Patients With Neovascular Age-Related Macular Degeneration

Acta Ophthalmologica
MedicineOphthalmology
2017English

Aflibercept for Neovascular Age-Related Macular Degeneration

Cochrane Database of Systematic Reviews
2016English

Choroidal Blood Flow After the First Intravitreal Ranibizumab Injection in Neovascular Age-Related Macular Degeneration Patients

Acta Ophthalmologica
MedicineOphthalmology
2018English

Characteristics of Eyes With Secondary Loss of Visual Acuity Receiving Variable Dosing Ranibizumab for Neovascular Age-Related Macular Degeneration

Graefe's Archive for Clinical and Experimental Ophthalmology
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2011English

Peripapillary Choroidal Thickness After Intravitreal Ranibizumab Injections in Eyes With Neovascular Age-Related Macular Degeneration

BMC Ophthalmology
MedicineOphthalmology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy